BiotechTube

Pirtobrutinib and rituximab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma (MCL)

Conditions

Mantle Cell Lymphoma (MCL)

Trial Timeline

Sep 30, 2025 → Dec 1, 2032

NCT ID
NCT07285590

About Pirtobrutinib and rituximab

Pirtobrutinib and rituximab is a phase 2 stage product being developed by Eli Lilly for Mantle Cell Lymphoma (MCL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07285590. Target conditions include Mantle Cell Lymphoma (MCL).

What happened to similar drugs?

1 of 6 similar drugs in Mantle Cell Lymphoma (MCL) were approved

Approved (1) Terminated (1) Active (4)
✅Acalabrutinib capsuleAstraZenecaApproved
🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
🔄Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
🔄Acalabrutinib + Bendamustine + Rituximab + PlaceboAstraZenecaPhase 3
🔄Sonrotoclax + Zanubrutinib + PlaceboBeOne MedicinesPhase 3
❌parsaclisib + rituximab + bendamustine + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07285590Phase 2Recruiting

Competing Products

20 competing products in Mantle Cell Lymphoma (MCL)

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
42
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
42
enzastaurinEli LillyPhase 2
35
AbemaciclibEli LillyPhase 2
35
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
44
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
42
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
35
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
40
VenetoclaxAbbViePhase 2
35
Ibrutinib + VenetoclaxAbbViePhase 2
35
ABT-199 and Ibrutinib CombinationAbbViePhase 1
29
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
27
Acalabrutinib capsuleAstraZenecaApproved
43
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
39
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
42
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
39
Acalabrutinib + RituximabAstraZenecaPhase 2
42
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
29
Acalabrutinib + Lenalidomide + Rituximab + ObinutuzumabAstraZenecaPhase 2
39